Biotech Values

[loridans]

Dendreon has their day with the FDA on March 29. Provenge, IMO, will be approved, although the whole controversy on immunomodulators makes it challenging.

Calculated risk. If no FDA approval next week--the stock gets clocked back to $2. But if it is approved--$10-$14 is probable.

There is a good overview on prospects for DNDN at thestreet.com that might interest biotech investors here.